CARDIOME PHARMA CORP Conference Call to discuss interim results from the Phase 2a pilot study for RSD1235 - Final.

Original Source: FD (FAIR DISCLOSURE) WIRE

OPERATOR: Good morning, ladies and gentlemen, thank you for standing by. Welcome to the Cardiome Pharma oral Phase IIa interim results conference call. At this time, all participants are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. (OPERATOR INSTRUCTIONS) I would like to remind everyone that this conference call is being recorded on Monday, July 24, 2006, at 6 AM Pacific Time. I will now turn the conference over to Mr. Don Graham, Director of Corporate Communications. Please go ahead, sir.

DON GRAHAM, DIRECTOR, CORPORATE COMMUNICATIONS, CARDIOME PHARMA CORP.: Thank you, Melissa. Good morning, everyone. Thank you for calling in to our conference call today to discuss our oral Phase IIa results. As Melissa said, my name is Don Graham, Director of Corporate Communications; and with me today and dialing in is Bob Rieder, Chief Executive Officer of Cardiome.

BOB RIEDER, VICE CHAIRMAN, CEO, CARDIOME PHARMA CORP.: Good morning, everyone.

DON GRAHAM: In our office with me is Doug Janzen, President and Chief Business Officer with Cardiome.

DOUG JANZEN, PRESIDENT, CHIEF BUSINESS OFFICER, CARDIOME PHARMA CORP.: Good morning, everyone.

DON GRAHAM: And again, dialing in is -- with me is Chuck Fisher, Executive Vice President and Chief Medical Officer.

CHUCK FISHER, CHIEF MEDICAL OFFICER, CARDIOME PHARMA CORP.: Good morning, everyone.

DON GRAHAM: Before we proceed, let me first discuss our forward-looking statements disclaimer. Any statements, expectations, and assumptions contained in this presentation that do not describe historical facts and discuss the effects of anticipated drugs or compounds, the successful integration and commercial viability of acquired intellectual property or other assets, the anticipated size of commercial markets for our current and future products, and projected results of our operations constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

Any forward-looking statements contained in this presentation are based on the Company's current expectations, are not guarantees of future performance, and are subject to a number of risks and uncertainties. Such risks and other risks are identified in our filings with the U.S. Securities and Exchange Commission, including but not limited to those appearing in Exhibit 1.1 under the heading Risk Factors to our annual report on Form 40-F filed with respect to our fiscal year ended December 31, 2005.

Now that the formalities are finished, I would like to pass this conference call over to Mr. Bob Rieder.

BOB RIEDER: Thank you, Don, and thank you to all of you for joining us on this very auspicious location in Cardiome's history. Up until this point in our development, most of our energy and effort and success has been in the intravenous development of RSD1235. I think the world in general has rightfully taken the viewpoint that because a drug works on the intravenous side, it may not necessarily work on the oral application.

While there is still a very long way to go in this program, we now have some tangible, real evidence of efficacy in relation to the oral applicability of the program.

This is very, very important to us as a Company, quite clearly. It is important both in our ability to now generate value from a second program; and also, and even more importantly, our ability to bring benefit to patients who are sorely in need of a therapy that helps them to safely and effectively stay in normal heart rhythm longer.

We are very, very encouraged by these results, all the more so because they took place at the low-dose end of the spectrum, and really look forward to continuing to develop this new asset within Cardiome as we go forward. So with that as background and preamble, let me now pass the meeting over to Doug Janzen.

DOUG JANZEN: Thanks, Bob. I certainly want to share Bob's comments about how excited we are with these results. I want to make clear to those of you on the line this is just an interim analysis. We expect full analysis of both the 300-mg cohort and the 600-mg cohort to occur here later on this quarter.

One of the reasons we are so excited is this analysis that we have reported today is based on the 300-mg cohort against just half of the placebo population. Those of you who understand stats recognize that it has in it a smaller placebo group; certainly could …